ALNYLAM PHARMA (DUL MU) stock market data APIs
€348.9161
-1.26(-0.4%)
as of December 23, 2025
Try our APIs with
free plan!
ALNYLAM PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for DUL.MU.
Prev. Close
348.9161
Open
347.6584
High
349.9426
Low
345.886
52 wk Range
192.15-419
Market Cap
18 390 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALNYLAM PHARMA data using free add-ons & libraries
Get ALNYLAM PHARMA Fundamental Data
ALNYLAM PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALNYLAM PHARMA News
New
What PeptiDream (TSE:4587)'s New Oral IL-17 Program and RNAi Milestone Mean For Shareholders
PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development portfo...
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strateg...
Alnylam’s Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY)
In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone...
Is It Too Late to Consider Alnylam After a 67.8% Surge in 2025?
If you are wondering whether Alnylam Pharmaceuticals at around $392 a share still offers value after a huge run, you are not alone. This is exactly the question we will unpack here. Despite a choppy r...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
